Latest Partnerships News

Resolution Minerals Limited is set to pursue a dual-listing on the NASDAQ in Q4 2025, aiming to tap into deeper U.S. capital markets and enhance its profile among American investors. The move supports the development of its critical minerals Horse Heaven project in Idaho, aligning with U.S. national security interests.

Diatreme Resources has formalised a negotiation framework with the Gulaal People, setting the stage for collaborative development of its Northern Silica Project while prioritising cultural heritage and community benefits.

Spenda Limited has reported a record-breaking FY25 with cash receipts soaring 114% to $11.5 million and launched its APG Pay platform backed by a $50 million funding commitment. The company also trimmed operating costs by 39%, setting a leaner foundation for FY26 growth.

Australian Rare Earths Limited (ASX, AR3) reports successful metallurgical testwork at its Koppamurra Rare Earths Project, producing 34kg of Mixed Rare Earth Oxide from heap leach solutions, paving the way for streamlined, cost-effective rare earth processing.

Anson Resources has announced a maiden JORC lithium resource of 103,000 tonnes LCE at its Green River Project in Utah, with plans to expand through historic well re-entry and a new collaboration with POSCO for lithium extraction technology.

Yojee Limited has unveiled its next-generation MOSAIC platform prototype to strong industry acclaim, completed critical technical validation for its SmartYojee customs technology, and secured a $5.4 million capital raise to fuel growth and commercialisation.

Liontown Resources capped its first year at Kathleen Valley with over 300,000 tonnes of spodumene concentrate produced and a record $23 million in operating cash flow, despite a challenging lithium price environment. The company is on track to complete open pit mining by year-end and fully transition to underground operations by Q3 FY26.

VHM Limited has secured a crucial mining licence for its Goschen Rare Earths and Mineral Sands Project, alongside key domestic and international partnerships and a successful $8.6 million capital raise.

Careteq Limited reports a significant reduction in operating cash outflow and modest revenue growth for FY25, while facing delays in its key platform integration and a dispute with the ATO over R&D claims.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.